Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: J Heart Lung Transplant. 2014 Jun 23;33(12):1215–1222. doi: 10.1016/j.healun.2014.06.007

Figure 1. Serum levels of NGAL and Cystatin C in controls, patients with stable and severe HF, and on VAD support.

Figure 1

(1A) NGAL levels increase in correlation to clinical severity of HF and decrease following hemodynamic improvement after VAD placement. (*p<0.01 versus control; †p<0.05 versus moderate HF).